2-(4-hydroxyphenoxy)-2-methylpropionic acid methyl ester | 81466-36-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-hydroxyphenoxy)-2-methylpropionic acid methyl ester
• 英文别名: 2-(4-hydroxy-phenoxy)-2-methyl-propionic acid methyl ester；methyl 2-(4-hydroxyphenoxy)-2-methylpropionate；methyl 2-(4-hydroxyphenoxy)-2-methylpropanoate
• CAS: 81466-36-6
• 化学式: C₁₁H₁₄O₄
• 分子量: 210.23
• InChiKey: DTGYPQPWRCWWIM-UHFFFAOYSA-N

物化性质

• 沸点：
  320.5±17.0 °C(Predicted)
• 密度：
  1.158±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-hydroxyphenoxy)-2-methylpropionic acid methyl ester 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 caesium carbonate 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 2-(4-(3-(2-Chloro-4-(4-fluorophenoxy)phenoxy)propoxy)phenoxy)-2-methylpropanoic acid
  参考文献：
  名称：

  Design and synthesis of potent and subtype-selective PPARα agonists

  摘要：

  Beginning with a moderately potent PPAR gamma agonist 9, a series of potent and highly subtype-selective PPAR alpha agonists was identified through a systematic SAR study. Based on the results of the efficacy studies in the hamster and dog models of dyslipidemia and the desired pharmacokinetic data, the optimized compound 39 was selected for further profiling. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.022
• 作为产物：
  描述：

  4-苄氧基苯酚 在 palladium on activated charcoal 氢气 、 caesium carbonate 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 36.0h， 生成 2-(4-hydroxyphenoxy)-2-methylpropionic acid methyl ester
  参考文献：
  名称：

  1,3,5-Trisubstituted aryls as highly selective PPARδ agonists

  摘要：

  A series of highly potent and selective PPAR delta agonists is described using the known non-selective ligand GW2433 as a structural template. Compound 1 is bioavailable, potent (10 nM), and shows no cross-activity with other PPAR subtypes lip to 10 mu M, making it a useful tool in studying the biological effects of selective PPAR delta activation. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.079

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS<br/>[FR] COMPOSES ET COMPOSITIONS SERVANT DE MODULATEURS PPAR
  申请人：IRM LLC

  公开号：WO2005116000A1

  公开（公告）日：2005-12-08

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.

  这项发明提供了化合物，包括这些化合物的药物组合物，以及使用这些化合物来治疗或预防与过氧化物酶体增殖物激活受体（PPAR）家族的活性相关的疾病或紊乱的方法，特别是PPAR的活性。
• [EN] 1,2-AZOLE DERIVATIVES WITH HYPOGLYSEMIC AND HYPOLIPIDEMIC ACTIVITY<br/>[FR] DERIVES 1,2-AZOLE PRESENTANT UNE ACTIVITE HYPOGLYCEMIQUE ET HYPOLIPIDEMIQUE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2003099793A1

  公开（公告）日：2003-12-04

  A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, - O -, - S - and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents -OR4 (R4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  化合物的结构式（1），其中环A是一个环，可选地具有1到3个取代基；环B是一个1,2-唑环，可能进一步具有1到3个取代基；Xa、Xb和Xc相同或不同，每个都是键，-O-，-S-等；Ya是一个具有1到20个碳原子的二价脂肪烃残基；Yb和Yc相同或不同，每个是键或具有1到20个碳原子的二价脂肪烃残基；环C是一个可能进一步具有1到3个取代基的单环芳香环；R代表-OR4（R4是氢原子或可选择地取代的碳氢基团）等，或其盐或前药，可用作糖尿病的预防或治疗剂等。
• 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
  申请人：Maekawa Tsuyoshi

  公开号：US20060148858A1

  公开（公告）日：2006-07-06

  A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, —O—, —S— and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents —OR 4 (R 4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  化合物的化学式为(1)，其中环A是一个环，可以有1到3个取代基；环B是一个1,2-咪唑环，可以进一步具有1到3个取代基；Xa，Xb和Xc相同或不同，每个都是键，-O-，-S-等；Ya是具有1到20个碳原子的二价脂肪烃残基；Yb和Yc相同或不同，每个都是键或具有1到20个碳原子的二价脂肪烃残基；环C是一个单环芳香环，可以进一步具有1到3个取代基；R代表-OR4（R4是氢原子或可选的取代烃基）等，或其盐或前药，可用作预防或治疗糖尿病等的药物。
• Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders
  申请人：Dropinski F. James

  公开号：US20080039514A1

  公开（公告）日：2008-02-14

  A class of compounds having Formula I and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of developing conditions and sequelae that are associated with these diseases, such as atherosclerosis.

  具有I式和其药物可接受的盐的化合物类别，可用作治疗化合物，特别是用于治疗高脂血症、高胆固醇血症、脂质代谢异常和其他脂质紊乱，并延缓或降低与这些疾病相关的病症和后遗症的发生风险，例如动脉粥样硬化。
• Compounds and Compositions as Ppar Modulators
  申请人：Epple Robert

  公开号：US20080292608A1

  公开（公告）日：2008-11-27

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.

  本发明提供了化合物、包含该类化合物的制药组合物以及使用该类化合物治疗或预防与过氧化物酶体增殖物激活受体（PPAR）家族活性相关的疾病或疾病的方法。